CAMBRIDGE, Mass. & DALLAS--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, and University of Texas Southwestern Medical Center, one of the world's leading academic medical centers, today announced that they have entered into a sponsored research agreement. Catabasis Pharmaceuticals will sponsor research at UT Southwestern to further advance the scientific understanding of the molecular mechanism and effects of Catabasis’ CAT-2000 series of molecules on the SREBP (Sterol Regulatory Element-Binding Protein) pathway.
The CAT-2000 series of molecules is engineered by Catabasis using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform to inhibit the maturation of SREBP and reduce the expression of key proteins involved in LDL-C and triglyceride metabolism. SREBP is a master regulator of lipid metabolism and modulates the expression of multiple metabolic proteins, including PCSK9, HMG-CoA reductase, ATP citrate lyase, NPC1L1, FASN, ACC, and PNPLA3.
The CAT-2000 series of molecules target the SREBP pathway, which regulates multiple metabolic proteins involved in lipid metabolism, and has potential across a range of serious diseases, including hyperlipidemia and NASH. Catabasis is working with UT Southwestern to progress a novel potential treatment option that could serve patients with metabolic disorders.
The research is designed to help determine the potential effects of the CAT-2000 series on serious lipid disorders involving cholesterol, triglycerides, and glucose. These results will support development of the CAT-2000 series in hyperlipidemia and other SREBP-related metabolic disorders, such as NASH.
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company's SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company’s focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company's technology and pipeline of drug candidates, please visit www.catabasis.com.
About University of Texas Southwestern Medical Center
UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty includes many distinguished members, including six who have been awarded Nobel Prizes since 1985. The faculty of more than 2,700 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to about 92,000 hospitalized patients and oversee approximately 2.1 million outpatient visits a year.